Gadopiclenol Fda

In April of 2023 FDA released a draft guidance entitled Marketing Submission Recommendations for a Predetermined Change. This presentation outlined key components essential for assuring pharmaceutical quality focusing on quality communication.

This presentation provided an overview of comparative clinical endpoint BE study and Irritation/sensitization/adhesion studies. The FDA announced that it is requiring a new class warning and other safety measures for all gadolinium-based contrast agents.

The National Organization for Rare Disorders hosted a virtual event focused on the Food and Drug Administration's draft. Dr Baolin Zhang from FDA's Center for Drug Evaluation and Research presents comprehensive research on antibody.